Source comparison
Best NAD+ Dosage for Cellular Energy: Research Comparison
Nicotinamide Riboside (NR) 250–500mg daily Moderate (oral capsule) 40–60% at 500mg Strong. Multiple RCTs in humans Best-supported precursor for systemic NAD+ elevation; enzyme saturation above 750mg limits benefit of higher doses Nicotinamide Mononucleotide (N
This comparison does not assign a generated winner or score.
- Nicotinamide Riboside (NR)
- 250–500mg daily
- Moderate (oral capsule)
- 40–60% at 500mg
- Strong. Multiple RCTs in humans
- Best-supported precursor for systemic NAD+ elevation; enzyme saturation above 750mg limits benefit of higher doses
- Nicotinamide Mononucleotide (NMN)
- Moderate to high (depends on formulation)
- 40–50% at 500mg
- Moderate. Fewer human trials than NR
- Direct precursor pathway; sublingual forms increase bioavailability significantly; comparable efficacy to NR at equivalent doses
- Sublingual NMN
- 200–400mg daily
- High (bypasses first-pass metabolism)
- 50–70% at 300mg
- Limited. Small human trials
- 30–40% higher plasma NAD+ vs oral; cost premium justified for bioavailability gain
- Liposomal NR/NMN
- High (protected from gastric degradation)
- 55–75% at 300mg
- Emerging. Formulation-dependent
- Encapsulation protects precursors; effective dose 30% lower than standard oral
- Nicotinamide (NAM)
- 50–100mg daily
- Very high (direct salvage pathway)
- 20–30% at 100mg
- Strong but limited by sirtuin inhibition
- Effective at low doses but inhibits SIRT1 above 500mg, negating longevity benefits
- Nicotinic Acid (Niacin)
- 500–1000mg daily
- High but causes flushing
- Variable (diverted to other pathways)
- Strong for lipid metabolism, weak for NAD+
- Causes vasodilation (flushing); primarily used for cholesterol management, not cellular energy